Facts & Research

Facts

Patients who have survived COVID-19 are likely to have high levels of IgG antibodies towards the virus in their blood. These antibodies were used to assist the immune system in its fight against the virus. COVID-19 survivors can donate their plasma (the component of the blood that contains antibodies) which can then be transfused into other COVID-19 patients to aid in their healing. Preliminary data reveals that COVID-19 plasma transfusions significantly aided patient recovery and in some cases may have saved people in critical condition.

 

Here are some ways our donor initiative has impacted the state of blood plasma transfusions as a treatment option for COVID-19 patients:

We are currently the primary donor pool of convalescent COVID-19 blood plasma in the NY region and among the largest in the USA.

We are partnered with medical affiliates including the New York Blood Center, Mayo Clinic and Johns Hopkins.

Thousands of plasma donations have occurred or have been scheduled. We continue to add regions beyond the NY/NJ area.

Each plasma donation = 3 patients treated. Doctors on the front lines report markedly higher chances of recovery with convalescent COVID-19 plasma treatment.

Experimental Treatments for COVID-19

NOTE: These are treatments currently under investigation for COVID-19, NOT an endorsement of these treatments. Please ask and discuss with your treating physician(s) to determine whether relevant patients are appropriate candidates for treatment.

Convalescent Plasma for COVID-19 Treatment

New: Research Paper: Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy

Research Paper: Safety and efficacy of convalescent plasma therapy in 5,000 patients

Nature biotechnology: "Treatment of choice" for COVID-19

CNN: Opinion - Plasma may be the best option in the fight against Covid-19, but don't celebrate just yet

Coronavirus In Minnesota: Mayo Clinic Working On Convalescent Plasma Treatment For COVID-19


Research Paper: Effectiveness of convalescent plasma therapy in severe COVID-19 patients (PNAS)

American Medical Association: Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

The Journal of Clinical Investigation: Deployment of convalescent plasma for the prevention and treatment of COVID-19

 

Immunomodulatory Therapy for COVID-19 Treatment: Interleukin Inhibitors

 

Research Study: Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis

Research Study: Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies (NCBI)

Los Angeles Times: Emergency room doctor, near death with coronavirus, saved after experimental treatment

Immunomodulatory Therapy for COVID-19 Treatment: Stem Cell Therapies

 

Research Study: Pluristem Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure

83% Survival in COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome Treated in New York with Mesoblast’s Cell Therapy Remestemcel-L

© 2020 by Covid Plasma Initiative Foundation

The Yitzchok Lebovits COVID Plasma Initiative is dedicated in memory of R’ Yitzchok a"h Ben R’ Moshe Eliezer y"blt, who recently passed away. R' Yitzchok was a brother of Chaim Lebovits who has been a driving force behind every aspect of this initiative to bring this life-saving therapy to the people who need it.